Join us for a deep dive into hypertrophic cardiomyopathy (HCM) with Andrew Williford, PharmD, an assistant professor and cardiology specialist at UC San Diego Health. In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease. Dr. Williford also shares insights from his telehealth GDMT titration clinic and offers practical guidance for pharmacists encountering HCM across care settings.Show notes: Hypertrophic Cardiomyopathy Guideline Hub Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related